Name: Eli Lilly and Company Financial Statements
Creator: Quarter Results

Income statement quarterly history for Eli Lilly and Company (LLY).
Income Statement (Quarterly)	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Revenue	12,728,500,000	13,532,800,000	11,439,100,000	11,302,800,000
Cost of Revenue	2,224,200,000	2,403,800,000	2,170,800,000	2,170,200,000
Gross Profit	10,504,300,000	11,129,000,000	9,268,300,000	9,132,600,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	2,362,200,000	2,424,500,000	2,099,800,000	2,002,900,000
Operating Expenses	5,095,900,000	5,331,200,000	4,833,900,000	4,828,500,000
Operating Income	5,408,400,000	5,797,800,000	4,434,400,000	4,304,100,000
Interest Expense	243,700,000	224,700,000	192,700,000	183,600,000
Income Before Tax	3,456,100,000	5,038,700,000	1,588,400,000	3,517,200,000
Income Tax Expense	696,800,000	628,900,000	618,100,000	550,200,000
Net Income	2,759,300,000	4,409,800,000	970,300,000	2,967,000,000
Per Share
EPS	3.07	4.88	1.08	3.29
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Eli Lilly and Company (LLY).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	65,179,000,000	45,042,700,000	34,124,100,000	28,541,400,000	28,318,400,000
Cost of Revenue	10,564,000,000	8,418,300,000	7,082,200,000	6,629,800,000	7,312,800,000
Gross Profit	54,615,000,000	36,624,400,000	27,041,900,000	21,911,600,000	21,005,600,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	11,094,000,000	8,593,800,000	6,941,200,000	6,440,400,000	6,431,600,000
Operating Expenses	24,919,000,000	19,584,400,000	16,254,600,000	13,631,200,000	13,457,500,000
Operating Income	29,696,000,000	12,899,000,000	10,325,400,000	7,127,300,000	6,357,100,000
Interest Expense	795,300,000	780,600,000	485,900,000	331,600,000	339,800,000
Income Before Tax	25,729,900,000	12,680,400,000	6,554,600,000	6,806,400,000	6,155,500,000
Income Tax Expense	5,091,600,000	2,090,400,000	1,314,200,000	561,600,000	573,800,000
Net Income	20,638,300,000	10,590,000,000	5,240,400,000	6,244,800,000	5,581,700,000
Per Share
EPS	15.59	11.76	5.83	6.93	6.15
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Eli Lilly and Company (LLY).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	3,268,400,000	2,818,600,000	2,067,000,000	3,818,500,000
Short Term Investments	154,800,000	109,100,000	144,800,000	90,100,000
Net Receivables	13,275,400,000	11,336,200,000	8,558,900,000	8,127,200,000
Inventory	7,589,200,000	5,772,800,000	4,309,700,000	3,886,000,000
Total Current Assets	32,739,700,000	25,727,000,000	18,034,500,000	18,452,400,000
Property Plant Equipment	17,102,400,000	12,913,600,000	10,144,000,000	8,985,100,000
Goodwill and Intangibles	11,936,600,000	11,846,300,000	11,279,600,000	11,583,900,000
Total Assets	78,714,900,000	64,006,300,000	49,489,800,000	48,806,000,000
Liabilities
Account Payables	3,228,600,000	2,598,800,000	1,930,600,000	1,670,600,000
Short Term Debt	5,117,100,000	6,904,500,000	1,501,100,000	1,538,300,000
Total Current Liabilities	28,376,600,000	27,293,200,000	17,138,200,000	15,052,700,000
Long Term Debt	28,527,100,000	18,320,800,000	14,737,500,000	15,346,400,000
Total Liabilities	64,443,300,000	53,142,600,000	38,714,400,000	39,651,200,000
Shareholders Equity
Retained Earnings	13,545,000,000	10,312,300,000	10,042,600,000	8,958,500,000
Total Shareholders Equity	14,192,100,000	10,771,900,000	10,649,800,000	8,979,200,000

Balance sheet annual history for Eli Lilly and Company (LLY).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	3,268,400,000	2,818,600,000	2,067,000,000	3,818,500,000	3,657,100,000
Short Term Investments	154,800,000	109,100,000	144,800,000	90,100,000	24,200,000
Net Receivables	13,275,400,000	11,336,200,000	8,558,900,000	8,127,200,000	6,929,000,000
Inventory	7,589,200,000	5,772,800,000	4,309,700,000	3,886,000,000	3,980,300,000
Total Current Assets	32,739,700,000	25,727,000,000	18,034,500,000	18,452,400,000	17,462,100,000
Property Plant Equipment	17,102,400,000	12,913,600,000	10,144,000,000	8,985,100,000	8,681,900,000
Goodwill and Intangibles	11,936,600,000	11,846,300,000	11,279,600,000	11,583,900,000	11,216,500,000
Total Assets	78,714,900,000	64,006,300,000	49,489,800,000	48,806,000,000	46,633,100,000
Liabilities
Account Payables	3,228,600,000	2,598,800,000	1,930,600,000	1,670,600,000	1,606,700,000
Short Term Debt	5,117,100,000	6,904,500,000	1,501,100,000	1,538,300,000	8,700,000
Total Current Liabilities	28,376,600,000	27,293,200,000	17,138,200,000	15,052,700,000	12,481,600,000
Long Term Debt	28,527,100,000	18,320,800,000	14,737,500,000	15,346,400,000	16,586,600,000
Total Liabilities	64,443,300,000	53,142,600,000	38,714,400,000	39,651,200,000	40,807,900,000
Shareholders Equity
Retained Earnings	13,545,000,000	10,312,300,000	10,042,600,000	8,958,500,000	7,830,200,000
Total Shareholders Equity	14,192,100,000	10,771,900,000	10,649,800,000	8,979,200,000	5,641,600,000

Cash flow quarterly history for Eli Lilly and Company (LLY).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	10,590,000,000	5,240,400,000	6,244,800,000	5,581,700,000
Depreciation & Amortization	1,766,600,000	1,527,300,000	1,522,500,000	1,547,600,000
Stock Based Compensation	645,600,000	628,500,000	371,100,000	342,800,000
Change in Working Capital	-5,385,000,000	-3,055,000,000	-14,500,000	-1,022,600,000
Operating Cash Flow	8,817,900,000	4,240,100,000	7,084,400,000	7,260,700,000
Investing Activities
Capital Expenditure	-8,403,600,000	-7,392,100,000	-2,484,000,000	-1,873,200,000
Investments	-5,057,800,000	-7,392,100,000	-2,484,000,000	-1,309,800,000
Investing Cash Flow	-9,301,500,000	-7,152,700,000	-3,261,600,000	-2,762,300,000
Financing Activities
Debt Repayment	8,901,100,000	-8,649,900,000	-1,560,000,000	-1,905,400,000
Common Stock Issued/Repurchased	-2,500,000,000	-750,000,000	-1,500,000,000	-1,250,000,000
Dividends Paid	-4,680,400,000	-4,069,300,000	-3,535,800,000	-3,086,800,000
Financing Cash Flow	1,230,100,000	3,495,600,000	-5,406,700,000	-4,131,300,000
Summary
Free Cash Flow	414,300,000	-3,152,000,000	4,600,400,000	5,387,500,000
Net Change in Cash	449,800,000	751,600,000	-1,751,500,000	161,400,000

Cash flow annual history for Eli Lilly and Company (LLY).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	10,590,000,000	5,240,400,000	6,244,800,000	5,581,700,000	6,193,700,000
Depreciation & Amortization	1,766,600,000	1,527,300,000	1,522,500,000	1,547,600,000	1,323,900,000
Stock Based Compensation	645,600,000	628,500,000	371,100,000	342,800,000	308,100,000
Change in Working Capital	-5,385,000,000	-3,055,000,000	-14,500,000	-1,022,600,000	-747,400,000
Operating Cash Flow	8,817,900,000	4,240,100,000	7,084,400,000	7,260,700,000	6,499,600,000
Investing Activities
Capital Expenditure	-8,403,600,000	-7,392,100,000	-2,484,000,000	-1,873,200,000	-2,029,100,000
Investments	-5,057,800,000	-7,392,100,000	-2,484,000,000	-1,309,800,000	-1,387,900,000
Investing Cash Flow	-9,301,500,000	-7,152,700,000	-3,261,600,000	-2,762,300,000	-2,258,900,000
Financing Activities
Debt Repayment	8,901,100,000	-8,649,900,000	-1,560,000,000	-1,905,400,000	-276,500,000
Common Stock Issued/Repurchased	-2,500,000,000	-750,000,000	-1,500,000,000	-1,250,000,000	-500,000,000
Dividends Paid	-4,680,400,000	-4,069,300,000	-3,535,800,000	-3,086,800,000	-2,687,100,000
Financing Cash Flow	1,230,100,000	3,495,600,000	-5,406,700,000	-4,131,300,000	-3,137,100,000
Summary
Free Cash Flow	414,300,000	-3,152,000,000	4,600,400,000	5,387,500,000	4,470,500,000
Net Change in Cash	449,800,000	751,600,000	-1,751,500,000	161,400,000	1,319,600,000

Eli Lilly and Company (LLY)